Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair

Elena S Ratner*,1,5, Yong-Lian Zhu1,5, Philip G Penketh1, Julie Berenblum1, Margaret E Whicker1, Pamela H Huang2, Yashang Lee3, Kimiko Ishiguro1, Rui Zhu4, Alan C Sartorelli4 and Z Ping Lin*,1,5

1Department of Obstetrics, Gynecology & Reproductive Sciences, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA; 2Department of Pathology, New Haven, CT, USA; 3Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA and 4Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA

Background: Platinum resistance may be attributable to inherent or acquired proficiency in homologous recombination repair (HRR) in epithelial ovarian cancer (EOC). The objective of this study was to evaluate the efficacy of the small molecule inhibitor triapine to disrupt HRR and sensitise BRCA wild-type EOC cells to platinum-based combination therapy in vitro and in vivo.

Methods: The sensitivity of BRCA wild-type cancer cells to olaparib, cisplatin, carboplatin, doxorubicin, or etoposide in combination with triapine was evaluated by clonogenic survival assays. The effects of triapine on HRR activity in cells were measured with a DR-GFP reporter assay. The ability of triapine to enhance the effects of the carboplatin-doxil combination on EOC tumour growth delay was determined using a xenograft tumour mouse model.

Results: Platinum resistance is associated with wild-type BRCA status. Triapine inhibits HRR activity and enhances the sensitivity of BRCA wild-type cancer cells to cisplatin, olaparib, and doxorubicin. However, sequential combination of triapine and cisplatin is necessary to achieve synergism. Moreover, triapine potentiates platinum-based combination therapy against BRCA wild-type EOC cells and produces significant delay of EOC tumour growth.

Conclusions: Triapine promises to augment the clinical efficacy of platinum-based combination regimens for treatment of platinum-resistant EOC with wild-type BRCA and proficient HRR activity.

Ovarian cancer is the fifth leading cancer death in women and the most lethal gynaecologic malignancy in the United States, with more than 14,000 women dying of the disease each year and the 5-year relative survival rate is only 44% (Siegel et al, 2015). The current standard of care for patients with ovarian cancer is optimal surgical cytoreduction followed by carboplatin in combination with paclitaxel chemotherapy (du Bois et al, 2003). Ovarian cancer remains one of the most chemosensitive solid malignancies. Patients with advanced disease at time of presentation have a 65–70% chance of achieving complete clinical response after surgery and chemotherapy. However, the majority of women will experience recurrence and ultimately die of their disease due to tumour acquisition of chemoresistance (Bookman et al, 1996). Topotecan and liposomal doxorubicin (Doxil) are currently used as second-line therapy for platinum-resistant ovarian cancer (Gordon et al, 2001). Platinum-resistant women have a 10–15% chance of responding to second-line chemotherapy agents with a median overall survival of 9–10 months, and platinum refractory women have an objective response to second-line chemotherapy of <10% (Gordon et al, 2001).

Cisplatin and carboplatin are platinum-containing anticancer agents that cause predominantly intrastrand crosslinking of DNA (85–90%) responsible for their cytotoxic activity (Fichtinger-Schepman et al, 1985; Siddik, 2003). The minor interstrand...
crosslinks accounted for about 1% of total platination are also widely considered to be most lethal lesions caused by platinum drugs. Proficiency in the repair of platinum-DNA crosslinking lesions has a critical role in the sensitivity of cancer cells to these agents. Nucleotide excision repair (NER) functions as a primary mechanism that efficiently repairs intrastrand crosslinks (O'Donovan et al., 1994). Homologous recombination repair (HRR) can also repair single-strand gaps owing to re-initiation of leading-strand synthesis downstream of intrastrand crosslinks (Li and Heyer, 2008). In contrast, the repair of interstrand crosslinks requires NER, HRR, and translesion synthesis (TLS) acting in a coordinated manner (Nijjima et al., 2005; Deans and West, 2011). Therefore, NER, HRR, and TLS contribute to platinum resistance dependent on the context of cancer types and the competency of these repair pathways (Zdравскеви et al., 2000).

Hereditary breast cancer and EOC are largely attributable to germline BRCA mutations causing defects in the HRR pathway for DNA double-strand break (DSB) repair (Ratner et al., 2012). PARP inhibitors impair the process of single-strand break repair and result in DSBs. Therefore, BRCA-mutated cancer cells are hypersensitive to PARP inhibitors (Bryant et al., 2005; Farmer et al., 2005). It is estimated that about 50% of high-grade serous EOC are defective in the HRR pathway (Cancer Genome Atlas Research Network, 2011). Epithelial ovarian cancer patients with BRCA mutations show greater clinical responses to the PARP inhibitor olaparib than EOC patients without BRCA mutations (Audeh et al., 2010; Kaye et al., 2012). Given that BRCA-mutant EOC also exhibits a marked increase in sensitivity and clinical response to platinum-based drugs (Sbagagias et al., 2004; Chethrit et al., 2008), it suggests that HRR is the primary mechanism for the repair of DNA damage caused by both classes of agents. Therefore, disruption of HRR can be exploited to augment the sensitivity of BRCA wild-type or HRR-proficient EOC to platinum and PARP inhibitor therapy.

Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone) is a small molecule inhibitor of ribonucleotide reductase (RRN) developed in our laboratory (Liu et al., 1992; Finch et al., 1999, 2000). Ribonucleotide reductase is a multimeric enzyme consisting of R2 and R1 subunits during the S phase of the cell cycle (Tanaka et al., 2006; Lin et al., 2004). It is responsible for the de novo synthesis of the deoxyribonucleoside diphosphates, the precursors of deoxyribonucleoside triphosphates (dNTPs) required for DNA replication and repair (Thelander and Rechard, 1979). As a potent iron chelator, triapine inactivates RRN by forming a triapine-RN complex that quenches the tyrosyl radical at the catalytic pocket within the R2 subunit (Sartorelli et al., 1976; Popovic-Bijelic et al., 2011). Therefore, triapine effectively stalls DNA replication by inhibiting de novo biosynthesis and depletion of purine nucleotides/dNTPs in proliferating cells (Cory et al., 1995; Lin et al., 2011). We have previously demonstrated that triapine abolishes olaparib-induced BRCA1 and Rad51 foci, and disrupts BRCA1 interaction with the MRN complex. Furthermore, triapine blocks CDK2-mediated CIP phosphorylation and DSB end resection, thereby sensitising EOC cells to PARP inhibitors (Lin et al., 2014). Preclinical and clinical studies show that triapine sensitises cancer cells to a range of DNA-damaging agents and radiation (Finch et al., 2000; Barker et al., 2006; Kunos et al., 2010). Given the clinical importance of platinum drugs in ovarian cancer treatment, the objective of this present study was to evaluate the effectiveness of triapine in the enhancement of currently used platinum-based regimens in BRCA wild-type EOC cells in vitro and in vivo.

**MATERIALS AND METHODS**

**Cell lines and chemicals.** MDA-MB231, BG-1, IGROV-1, SKOV-3, A2780-CP70, PEO1, PEO4 cancer cell lines were grown in DMEM/F12 (BG-1), RPMI (MDA-MB231, IGROV-1), McCoy's 5A (SKOV-3), and DMEM (A2780-CP70, PEO1, PEO4) media supplemented with 10% FBS and penicillin-streptomycin antibiotics. MDA-MB231 and SKOV-3 cells were purchased from ATCC (Manassas, VA, USA). BG-1 and IGROV-1 cells were obtained from Dr Joanne Weidhaas (Yale University); A2780-CP70 cells were provided by Dr Gil Mor (Yale University). PEO1 and PEO4 cells were provided by Dr Peter Glazer (Yale University). Cisplatin and carboplatin were purchased from EMD Millipore (Billerica, MA, USA), doxorubicin from Enzo Life Sciences (Farmingdale, NY, USA), etoposide from R&D Systems (Minneapolis, MN, USA), Doxil from Avanti Polar Lipids (Alabaster, AB, USA), and olaparib from Selleck (Houston, TX, USA), and Axon Medchem (Groningen, The Netherlands). Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone) and triapine isethionate were synthesised in our laboratory as previously described (Liu et al., 1992).

**Clonogenic assays.** Cells were plated at various densities in 6-well plates in triplicate. After 24 h of incubation, cells were treated with single drugs or drug combinations. After 10–21 days, colonies were fixed and stained with crystal violet solution, and counted to determine the % survival using a GelDoc imaging system with QuantityOne software (Bio-Rad, Hercules, CA, USA).

**HRR assays.** SKOV-3-DR-GFP cells were established as described previously (Lin et al., 2014); cells were transfected with the empty vector pcDNA-Neo or the I-SceI endonuclease expression vector pCtRAScel (provided by Dr Maria Jasin, Memorial Sloan-Kettering Cancer Center) (Pierce et al., 1999) using the TransFast reagent (Promega, Madison, WI, USA) according to the manufacturer’s protocol. Five hours after transfection, cells were treated with various concentrations of triapine for 48 h. For siRNA transfection, cells were transfected with 50 nm siRNA using Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA) for 16 h before transfection with pcDNA-Neo or pCBAScel plasmid and incubated for 48 h. Thereafter, cells were trypsinised and green fluorescence and side scatter of 50,000 cells were analysed by flow cytometry using an LSR II flow cytometer (BD Biosciences; San Jose, CA, USA). The cell population with an increase in GFP above the baseline level was gated to determine the percentage of GFP-positive cells. Data analyses were performed using the Flowjo software (Tree Star, Ashland, OR, USA). BRCA1, Rad51, and R2-RNR siRNAs have been described previously (Lin et al., 2004, 2014). BRCA2-siRNA (SMARTpool, siGENOME) was purchased from GE-Dharmacon (Lafayette, CO, USA).

**NHEJ assays.** The methodology has been described previously (Li et al., 2012). The pG3L-control plasmid (Promega) was linearised with the restriction enzyme HindIII and purified. SKOV3 cells were co-transfected with linearised pG3L-control and the internal control pRL-TK plasmids (Promega) at a 10:1 ratio using the TransFast reagent (Promega). After 2 h, cells were treated with various concentrations of triapine for 48 h. Cell lysates were assayed for firefly and renilla luciferase activities using the Dual Luciferase Assay System and a luminometer (Promega). The activity of firefly luciferase activity was normalised to that of renilla luciferase to correct for transfection efficiency. Overall NHEJ activity was expressed as a percentage of the luciferase activity in cells transfected with non-linearised pG3L-control plasmid. For siRNA-treated cells, cells were transfected with siRNA for 18 h before transfection with linearised pG3L-control and pRL-TK plasmids.

**Combination index and statistical analyses.** Combination index (CI) for evaluating the effects of two drugs in combination was performed using the CalcuSyn software (Biosoft, Cambridge, UK) based on the method of Chou and Talalay (1984). CI < 1, CI = 1, and CI > 1 represent synergism, additivity, and antagonism.
respectively. For statistical analyses, data were compared using the paired Student’s t-test. A P-value of <0.05 was considered as statistically significant.

**HPLC analysis.** Samples containing triapine in Tris-HCl or potassium buffer were mixed with an equal volume of CH<sub>3</sub>CN, and incubated for 10 min at room temperature then centrifuged at 10,000 g for 10 min. The samples were then analysed using an HPLC protocol, which involves two eluting buffers A (30% CH<sub>3</sub>CN, in 30 mM KPi, pH 7.4) and B (75% CH<sub>3</sub>CN, in 30 mM KPi, pH 7.4) and utilises a 5 micron 220 × 4.6 mm RP-18 C-18 reverse phase column (Applied Biosystems, Foster City, CA, USA). The flow rate was 0.66 ml per minute, starting with a mixture of 90% A and 10% B, for 5 min; this was followed by a linear gradient over the next 10 min to 100% B and continued at this composition for another 15 min before returning to the starting composition for 3 min. A UV/visible detector monitored the triapine elution at 355 nm. Triapine eluted as a sharp peak at ~5.1 min. The sensitivity of this method was insufficient to accurately determine the concentrations of triapine that were <1 μM.

**Spectroscopic determination of the reaction of triapine and cisplatin.** Reaction of triapine with cisplatin was monitored by following absorbance bleaching due to triapine loss at 355 nm versus time. The reaction kinetics was followed in 20 mM Tris-HCl buffer pH 7.0 and 37°C with regular time interval scans. The half-reaction time was ~20 min using 20 μM triapine and 500 μM cisplatin. These relatively high concentrations were used to speed the reaction and discover the fractional change in absorption upon complete reaction to enable accurate calculations under other conditions. Following an extended reaction time (100 min) with a 25-fold molar excess of cisplatin, the absorbance at 355 nm was decreased by 61% and this was assumed to represent the reaction end point. Cisplatin has no significant absorbance at 355 nm.

**Tumour xenografts.** The Yale University Institutional Animal Care and Use Committee approved the protocols for the *in vivo* animal studies in compliance with the US Public Health Policy on Humane Care and Use of Laboratory Animals. Five- to six-week-old female athymic Nude-Foxn1 nu mice were purchased from Harlan Laboratories (Indianapolis, IN, USA). SKOV-3 cells suspended in 100 μl McCoy’s 5A medium mixed with 50 μl Matrigel (BD Biosciences) were implanted s.c. in the right dorsal medial area (3.6 × 10<sup>6</sup> cells per mouse). Therapy was initiated 10 days after implantation when tumours were approximately 50–100 mm<sup>3</sup> in volume. A control group (2% DMSO) and the groups treated with triapine isethionate (dissolved in 2% DMSO, 10 mg kg<sup>−1</sup>) i.p. once daily for 5 consecutive days per week for a total of 4 weeks. Carboplatin (dissolved in water, 25 mg kg<sup>−1</sup>) and doxil (6 mg kg<sup>−1</sup>) were simultaneously given i.p. once on day 1 and day 15. For the group treated with the triple combination, mice were treated with triapine 6 h before doxil and carboplatin. Tumour size was measured three times per week using a digital caliper. Tumour volumes were calculated using the formula: length × width<sup>2</sup>/2. Body weights of mice were measured on every treatment day before administration and on the same schedule as tumour measurements during the 4-week treatment period. Tumours were excised immediately after euthanasia and fixed with 10% formalin for 72 h. Fixed tumour tissue was paraffin-embedded and sectioned for haematoxylin and eosin (H&E) staining.

**RESULTS**

Cancer cell lines exhibit a profile of platinum and PARP inhibitor sensitivity correlated with BRCA status. To correlate the BRCA function with platinum and PARP inhibitor sensitivity, a panel of cancer cell lines with defined BRCA status was examined for their sensitivity to cisplatin and olaparib by clonogenic assays. BG-1, MDA-MB231, CP70, SKOV-3, and PEO4 are BRCA wild-type cells. IGROV-1 is a BRCA1 heterozygous (BRCA1<sup>+/−</sup>) mutant (Foray et al., 1999) and PEO1 is a hemizygous BRCA2 mutant (Sakai et al., 2009). CP70 is a platinum-resistant EOC cell line derived from platinum-sensitive A2780 cells (Behrens et al., 1987). CP70, BG-1, and MBA-MB231 cells exhibited the highest degree of resistance to cisplatin, whereas PEO1 cells displayed the highest sensitivity to cisplatin (Figure 1A, D and E). SKOV-3, PEO4, and CP70 cells were the most resistant while PEO1 cells were the most sensitive to olaparib (Figure 1B, D and E). IGROV-1 cells manifested an intermediate sensitivity to both cisplatin and olaparib at levels between BRCA wild-type and mutant cancer cell lines (Figure 1A, B and E). All cell lines exhibited a similar sensitivity to triapine at concentrations up to 0.5 μM, whereas PEO1, BG-1, and IGROV-1 became increasingly sensitive at 0.75 μM (Figure 1C–E). These results suggest that platinum- and PARP inhibitor-induced DNA lesions are commonly repaired by the functional BRCA pathway that upholds resistant phenotypes of breast cancer and EOC cells.

**Triapine potentiates platinum combination therapy**

Triapine potentiates platinum combination therapy

BRITISH JOURNAL OF CANCER

www.bjcancer.com | DOI:10.1038/bjc.2016.54

779
cisplatin for 1 h, followed by exposure to 0.5 μM triapine continuously in the absence of cisplatin. In sharp contrast to the concentration-dependent antagonistic interaction by simultaneous treatment with triapine and cisplatin (Figure 2B and Supplementary Table 1B), pre-treatment with cisplatin for 1 h before continuous triapine exposure led to synergistic sensitisation of BG-1 cells to the entire range of cisplatin concentrations (Figure 3C and Supplementary Table 2A). Likewise, SKOV-3 cells pre-treated with cisplatin for 1 h followed by exposure to 0.75 μM triapine exhibited synergistic sensitisation to an entire range of cisplatin concentrations (Figure 3D and Supplementary Table 2B). Sequential treatment of MDA-MB231 with cisplatin and triapine also produced synergistic sensitisation, whereas concurrent treatment led to antagonism (Supplementary Figure 1).
Inhibition of RNR by triapine or siRNA suppressed HRR but not NHEJ activities. To substantiate that triapine sensitised BRCA wild-type cancer cells by inhibiting HRR, the effects of triapine on HRR activity were determined. SKOV-3-DR-GFP cells were transiently transfected with the I-SceI gene to generate a DSB in the truncated GFP gene. Transfection with the I-SceI gene effectively induced HRR activity as detected by an increase in the GFP-positive cell population. siRNA-mediated depletion of BRCA1, BRCA2, and Rad51 significantly suppressed I-SceI-induced HRR activity (Figure 4A and B). Transient transfection with BRCA2-siRNA was confirmed to sensitize SKOV-3 cells to olaparib and cisplatin (Supplementary Figure 2). Notably, depletion of the R2 subunit of RNR by siRNA considerably suppressed HRR activity. In consistent with this finding, triapine that targets R2 subunit to inhibit RNR activity also suppressed HRR activity in a concentration-dependent manner (Figure 4C and Supplementary Figure 3).

To investigate whether triapine treatment had impacts on NHEJ activity, a pGL3 luciferase-based NHEJ assay was performed. The restriction enzyme HindIII cuts DNA at a site between the promoter and coding region of luciferase gene in the pGL3-control plasmid. NHEJ rejoins the ends and restores luciferase activity in cells. SKOV-3 cells were transfected with HindIII-linearised pGL3-luciferase plasmid and subsequently treated with various concentrations of triapine. Depletion of R2-RNR, BRCA1, and BRCA2 had no effects on NHEJ (Figure 4D). Triapine did not inhibit NHEJ activity but enhance the activity marginally, though not significantly throughout, with increasing concentrations of triapine (Figure 4E).

Addition of DSB-inducing agents further augments synergistic effects of sequential combination of triapine and cisplatin. Etoposide and doxorubicin inhibit topoisomerase II, and therefore cause DSBs (Caldecott et al, 1990; Ciszewski et al, 2014). Thus, HRR is required to mitigate the lethality of these agents. Since that direct reaction between triapine and etoposide/doxorubicin is unlikely, SKOV-3 cells were simultaneously treated with triapine and these agents. Treatment with triapine led to synergistic sensitisation of SKOV-3 cells to etoposide or doxorubicin (Figure 5A and B).

We determined whether addition of doxorubicin further augmented the effects of sequential combination of triapine and cisplatin on BRCA wild-type EOC cells. SKOV-3 cells were pretreated with cisplatin for 1 h and then exposed continuously to triapine and doxorubicin. The cisplatin and doxorubicin combination resulted in synergistic sensitisation of SKOV-3 cells only at the highest concentrations (Figure 5C and D). Inclusion of triapine led to enhancement of cell kill by the cisplatin–doxorubicin combination at all concentrations. Analysis of CI values confirmed that the synergism by the triple combination of triapine, cisplatin, and doxorubicin was considerably greater than the combinations of the double combination of cisplatin and doxorubicin (Figure 5D).

Triapine markedly enhances the effects of platinum-based combination therapy on tumour growth delay in EOC xenografts. To corroborate the effectiveness of the triple combination in vivo, a similar sequential combination strategy was evaluated using an EOC xenograft model. Nude mice bearing SKOV-3 tumour were treated with triapine for 6 h preceding the administration of the combination of carboplatin and doxil. Tumour sizes and mouse body weights were measured, and histological manifestations of tumour tissue were examined. Triapine treatment alone produced little effects on tumour growth delay (Figure 6A). Treatment with Doxil or carboplatin alone had moderate inhibitory effects on tumour growth (Supplementary Figure 4). The combination of carboplatin and doxil initially caused inhibition of tumour growth, but gradually lost its effects after day 28. Importantly, addition of triapine to the carboplatin–doxil combination led to a marked and significant enhancement of tumour growth delay compared with the carboplatin–doxil combination.
combination. In addition, monitoring changes in body weights showed no evident toxicity caused by drug treatment (Figure 6B). Furthermore, H&E stain of tumour tissue revealed that triapine added to the carboplatin–doxil combination resulted in shrinkage and disappearance of nuclei. In contrast, triapine and the carboplatin–doxil combination did not cause apparent changes in histological features of tumour tissue compared with that of the vehicle-treated control (Figure 6C).

**DISCUSSION**

HRR has been increasingly considered as an important DNA repair mechanism underlying intrinsic and acquired resistance to platinum-based chemotherapy. Hereditary EOC with deleterious BRCA mutations manifests hypersensitivity to PARP inhibitor and platinum therapy as a result of defective HRR (Ratner et al, 2012). Unfortunately, the majority of BRCA-mutated EOC eventually develops platinum resistance. It has been reported that functional restoration of HRR by secondary mutations of BRCA genes in BRCA-mutant EOC with platinum resistance occurs in patients who have previously received platinum-based chemotherapy (Sakai et al, 2008, 2009; Swisher et al, 2008; Norquist et al, 2011). Furthermore, additional novel mechanisms that restore HRR function and cause PARP inhibitor and platinum resistance have been identified, including downregulation of 53BP1 (Jaspers et al, 2013), loss of CHD4 (Guillemette et al, 2015), and stabilisation of mutant BRCA1 protein (Johnson et al, 2013). Given the importance of HRR as a target for current and future ovarian cancer treatment, our findings on the ability of triapine to suppress HRR and sensitise BRCA wild-type cancer cells represent a novel and translational approach to circumvent the problem of therapeutic resistance conferred by restored or acquired HRR proficiency.

We have previously shown that siRNA-mediated knockdown of R2-RNR reduces RNR activity and sensitises BRCA wild-type HCC116 cells to cisplatin (Lin et al, 2004, 2007). In this present study, triapine that targets R2-RNR produces synergistic sensitisation of BRCA wild-type cancer cells to olaparib, cisplatin, etoposide, and doxorubicin (Figures 2 and 5). Owing to the chemical interaction between triapine and platinum drugs, sequential treatment strategy for the combination is necessary to achieve the synergistic effects. Alternatively, identification of small molecule inhibitors that can disrupt protein–protein interactions between R1 and R2 subunits of RNR may preclude the problem of triapine–platinum interactions. Such small molecule inhibitors of RNR have been recently identified (Zhou et al, 2013).

Although NHEJ may not be impacted by triapine (Figure 4E), we cannot rule out the possibility that triapine interferes with other DNA repair mechanisms, given that NER is primarily required for platinum-DNA crosslinks. We have previously shown that reduced
Triapine potentiates platinum combination therapy

BRITISH JOURNAL OF CANCER

Figure 5. Effects of doxorubicin on sequential combination of triapine and cisplatin. SKOV-3 cells were concurrently treated with 0.75 μM triapine and various concentrations of etoposide (A) or doxorubicin (B). Clonogenic survival was determined. Data are means ± s.d. *; CI < 1. Cells were treated with various concentrations of cisplatin (1-h pulse treatment), doxorubicin, the cisplatin and doxorubicin combination at a fixed ratio (1000:1), or the cisplatin and doxorubicin combination plus 0.75 μM triapine. Clonogenic survival was then determined. Data are means ± s.d. (C) CI values for the combinations are shown in the bar graph (D).

dNTP supply by limiting RNR activity has negative impact on the efficiency of NER and cell survival in response to platinum-induced DNA damage (Lin et al, 2004, 2007). It is conceivable that the activities of DNA polymerases involved in DNA repair, such as pol β, δ, and ε (Wood and Shivji, 1997), may be diminished by depletion of dNTPs due to triapine treatment. However, the effects of triapine were not limited to the combinations with platinum drugs. Triapine was also active in combination with other DNA-damaging agents, including olaparib, etoposide, doxorubicin (Figures 2 and 5), and radiation (Barker et al, 2006). In our previous studies, we have found that triapine abrogates BRCA1 foci and impairs etoposide-induced DSB end resection (Lin et al, 2014).

In conjunction with the data of DR-GFP assays, triapine disrupts HRR as a major, if not only, mechanism to sensitise BRCA wild-type EOC cells to a range of DNA-damaging agents that directly or indirectly cause DSBs.

Systematic inhibition of HRR by small-molecule inhibitors like triapine raises the concern about its potential toxic effects on normal replicating cells and tissues. A large body of evidence indicates that wild-type p53 suppresses HRR activity (Mekeel et al, 1997; Bertrand et al, 2004; Gatz and Wiesmuller, 2006). Therefore, we postulate that normal tissues have restricted HRR and are less likely to be impacted by systematic inhibition of HRR by triapine. In contrast, the majority of EOC cells lacking functional p53 are expected to exhibit a greater usage of HRR for DSBs and therefore a greater susceptibility to the inhibitory effects of triapine. Our data of DR-GFP assays confirm that expression of wild-type p53 significantly suppresses I-SceI-induced HRR in SKOV3 cells (Supplementary Figure 5). In contrast, expression of mutant p53 (R175H) (Liu et al, 2010) appears to stimulate HRR although not statistically significant. SKOV3 cells are considered being p53-null as the protein level of wild-type p53 is undetectable. Furthermore, clinical studies of triapine in combination with cisplatin and radiation have shown that the half-life of plasma concentration of triapine is 2 h after a 2-h triapine (25 and 50 mg m⁻²) infusion and the regimens are well tolerated by patients (Kunos et al, 2010). Several strategies that impair HRR pathways, such as inhibitors of EGFR, HDAC, or HSP90, have been demonstrated to sensitise tumour cells to chemotherapy and radiation in vivo (Chernikova et al, 2012). Considering these preclinical and clinical findings, we propose that inhibition of HRR by triapine in combination with other genotoxic modalities may not inflict additional toxicity to patients if dosing schedules of triapine are properly implemented.

Following successful phase I and phase II clinical trials, Kunos and colleagues reported 3-year efficacy end points of triapine, cisplatin, and radiation combination therapy, demonstrating 4% relapse rate, 80% disease-free survival, and 82% overall survival in 24 patients with stage IB2-IIIB cervical cancer (Kunos and Sherertz, 2014). Given these promising results, triapine is currently being advanced to a phase II randomised trial with this triapine-based combination for treatment of advanced cervical and vaginal cancers. In contrast, a phase I study on platinum-resistant EOC showed that triapine co-administration with cisplatin produced a 17% partial response and 33% stable disease, with a duration of less than 6 months (Kunos et al, 2012). Cervical and vaginal cancer patients were given triapine (25 mg m⁻²) three times a week for 5 weeks.
weeks, while EOC patients were given triapine (96 mg·m⁻²) in a consecutive 4-day cycle for every 21 days. As impairment of HRR, rather than direct DNA damaging effects, by triapine may underlie the enhanced therapeutic efficacy of cisplatin and radiation, it is conceivable that a prolonged exposure of triapine at a lower concentration is better suited, and therefore contributes to the success of the cervical cancer trials.

The carboplatin–doxil combination is a clinical regime for recurrent and late-relapse EOC (Pujade-Lauraine et al, 2010; Gladieff et al, 2012). The concentrations of carboplatin and doxil used (25 mg·kg⁻¹ and 6 mg·kg⁻¹, respectively) in our xenograft studies were much lower than the doses given clinically (AUC (equivalent to 100 mg·kg⁻¹), 30 mg·m⁻² (equivalent to 16 mg·kg⁻¹), respectively) to EOC patients (Pujade-Lauraine et al, 2010). Therefore, addition of triapine offers potential benefits in augmenting therapeutic efficacy and reducing toxicity of the combination of carboplatin and doxil. To avoid the potential interaction between carboplatin and triapine in vivo, we treated mice with triapine 6 h before administration with carboplatin based on the assumption that the plasma level of triapine has considerably declined at the time. Future investigation on the pharmacokinetics of triapine in mice will provide the information for determining the optimal timing of triapine and carboplatin administration. In conclusion, our findings demonstrate a proof-of-concept approach and provide a strong rationale for inclusion of triapine in platinum-based combination therapy to overcome platinum resistance and to achieve an improved clinical outcome in future EOC trials.
trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17): 1320–1329.
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA1 mutant cells as a therapeutic strategy. Nature 434(7035): 917–921.
Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J (1985) Adducts of the antitumor drug cis-diaminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24(3): 707–710.
Finch RA, Liu MI, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, Sartorelli AC (2000) Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 59(8): 983–991.
Finch RA, Liu MI, Cory AH, Cory JG, Sartorelli AC (1999) Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 39: 3–12.
Foray N, Randrianarison V, Marot D, Perroud M, Lenoir G, Feunteun J (1999) Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2. Oncogene 18(51): 7334–7342.
Gatz SA, Wiesmuller L (2006) p53 in recombination and repair. Cell Death Differ 13(6): 1003–1016.
Gladieff P, Ferrary A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Inactivation of p53 results in high rates of homologous recombination in human cells. Oncogene 14(15): 1847–1857.
Nohjima K, Hocking H, Saberi A, Fukushima T, Kikuchi K, Yoshimura M, Orelli BJ, Bishop DK, Hirano S, Ohteki M, Ishiai M, Yamamoto K, Takata M, Arakawa H, Buerstedde JM, Yamazoe M, Kawamoto T, Araki K, Takahashi JA, Hashimoto S, Takeda M, Sonoda E (2005) Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 65(24): 11704–11711.
Mekehr KL, Tang W, Kachnic LA, Luo CM, DeFrank JS, Powell SN (1997) Identification of p53 mutants in results of high resolution in homologous recombination. Oncogene 18(15): 5272–5276.
Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, O'Donovan A, Davies AA, Moggs JG, West SC, Wood RD (1994) XPG (Xeroderma pigmentosum group G) homolog is required for homologous recombination and embryonic development. Genes Dev 8(1): 1–12.
Pierce AJ, Johnson RD, Thompson LH, Jasin M (1999) XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 13(19): 2448–2459.
Kaminski A, Wierzbicki P, Hsu SY, Rabiee A, Arif S, Sartorelli AC, Belcourt MF, Cory JG, Belcourt M, Liu J, Cory JG, Brown C, Sartorelli AC (2007) Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress. Biochem Pharmacol 73(6): 760–772.
Lin, Z., Belcourt MF, Cory JG, Sartorelli AC (2004) Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. J Biol Chem 279(26): 27030–27038.
Lin, Z., Pan Y, Lin F, Belcourt MF, Li P, Cory JG, Glazer PM, Sartorelli AC (2011) Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage. Mol Pharmacol 80(6): 1000–1012.
Li, D.P., Song, H, Yu (2010) A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 29(7): 949–956.
Lin, MC, Lin TS, Sartorelli AC (1992) Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazide. J Med Chem 35(20): 3672–3677.
Aubert B, Ovejero C, Sartorelli AC (1992) Synthesis and biological activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazide. Mol Pharmacol 42(6): 1422–1431.
O’Donovan A, Davies AA, Miron A, West SC, Wood RD (1994) XPG (Xeroderma pigmentosum group G) homolog is required for homologous recombination and embryonic development. Genes Dev 8(1): 1–12.
Morton N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Inactivation of p53 results in high rates of homologous recombination in human cells. Oncogene 18(15): 5272–5276.
Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, O’Donovan A, Davies AA, Moggs JG, West SC, Wood RD (1994) XPG (Xeroderma pigmentosum group G) homolog is required for homologous recombination and embryonic development. Genes Dev 8(1): 1–12.
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1): 5–29.

Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68(8): 2581–2586.

Tanaka H, Arakawa H, Yamaguchi T, Shirai K, Fukuda S, Matsu K, Takei Y, Nakamura Y (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404(6773): 42–49.

Thelander L, Reichard P (1979) Reduction of ribonucleotides. Annu Rev Biochem 48: 133–158.

Wood RD, Shivji MK (1997) Which DNA polymerases are used for DNA-repair in eukaryotes? Carcinogenesis 18(4): 605–610.

Zdraveski ZZ, Mello JA, Marinus MG, Essigmann JM (2000) Multiple pathways of recombination define cellular responses to cisplatin. Chem Biol 7(1): 39–50.

Zhou B, Su L, Hu S, Hu W, Yip MLR, Wu I, Gaur S, Smith DL, Yuan Y-C, Synold TW, Horne D, Yen Y (2013) A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. Cancer Res 73(21): 6484–6493.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)